Gamma announces Astrea, Avacta partnership

By The Science Advisory Board staff writers

December 23, 2020 -- Life sciences firm Gamma Biosciences has announced a licensing agreement between chromatography developer Astrea Bioseparations and biotherapeutic and reagent developer Avacta.

The licensing agreement gives Astrea access to Avacta's Affimer reagent technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include chemical and biological platforms for customer development programs, Gamma said.

Gamma Biosciences acquires Nanopareil
Gamma Biosciences has purchased nanofiber membrane product developer Nanopareil.
Avacta, Daewoong partner on COVID-19 therapy
Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19...
Avacta's Affimer reagent may neutralize SARS-CoV-2
Avacta Group, the developer of Affimer biotherapeutics and reagents, announced that several Affimer reagents block the interaction between SARS-CoV-2's...

Copyright © 2020

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter